TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04665973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic patient education : oral semi-structured interview
Description: The physiotherapist discusses and goes through each page of the booklet and involves the patient as much as possible. He demonstrates the exercises proposed in the booklet and then ask the patient to perform them in front of him. The physiotherapist tries to identify the patient's needs and suggests different ways to ensure that the patient has different opportunities to maintain the best possible level of PA

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic patient education : booklet (passive)
Description: The booklet (11 pages): explains why it is important to maintain a good level of PA as part of cancer treatment and reviews the most common side effects of cancer therapy and the relative importance of PA in combating these effects (pages 2-3) ; defines PA, its modalities and possible security precautions (pages 4-5), suggests exercises to be performed oneself and a target intensity to be reached (pages 6-8), provides a roadmap to be completed oneself (pages 9-10), and outlines procedures for joining an exercise medicine group (page 11).
Study: NCT06397053

Intervention type: PROCEDURE
Intervention: robotic surgery
Description: robotic surgery

Intervention type: PROCEDURE
Intervention: robotic surgery
Description: robotic surgery
Study: NCT01490840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Strength training exercises are performed against own body weight or with training aids like elastic rubber bands or gym balls. All exercises are home-based. To increase balance and core stability, a subset of exercises is performed on shaky ground and/or one-legged. Exercise intensity, duration and frequency are individually assigned by a sports therapist. For each muscle group, a set of exercises of increasing difficulty allows for individual and progressive training adaption. Therapists can choose from an exercise database of approximately 150 different strength exercises with different graduation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Strength training exercises are performed against own body weight or with training aids like elastic rubber bands or gym balls. All exercises are home-based. To increase balance and core stability, a subset of exercises is performed on shaky ground and/or one-legged. Exercise intensity, duration and frequency are individually assigned by a sports therapist. For each muscle group, a set of exercises of increasing difficulty allows for individual and progressive training adaption. Therapists can choose from an exercise database of approximately 150 different strength exercises with different graduation.
Study: NCT00823030

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Urodynamic study
Description: A small catheter will be inserted into the bladder and water will slowly be instilled through the catheter and into your bladder. A series of measurements will then be taken to assess your bladder's capacity to hold liquid, the average and maximum urine flow rates, as well as bladder filling and leak point pressure readings.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urodynamic study
Description: A small catheter will be inserted into the bladder and water will slowly be instilled through the catheter and into your bladder. A series of measurements will then be taken to assess your bladder's capacity to hold liquid, the average and maximum urine flow rates, as well as bladder filling and leak point pressure readings.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 20 cc of alkalinized lidocaine will be injected after the first UDS

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 20 cc of normal saline will be injected into the bladder after the first UDS
Study: NCT01046045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: everolimus at an initial daily loading dose between 1 and 4 mg dose of everolimus will be adjusted to maintain a trough everolimus level between 5 and 12 ng/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: everolimus at an initial daily loading dose between 1 and 4 mg dose of everolimus will be adjusted to maintain a trough everolimus level between 5 and 12 ng/mL
Study: NCT01356771

Intervention type: OTHER
Group type: OTHER
Intervention: Surveys & Mailed Materials
Description: Phase I: Patients are screened for their level of risk for skin cancer. They will complete a survey and undergo a skin exam administered by the research staff. Moderate- and high-risk persons will be invited to enroll in Phase II.~Phase II: Three sets of materials will be sent in the mail over the course of 6 weeks. Pamphlets will contain information about ways to reduce participant's risk of skin cancer, including sun protection practices, benefits of skin screening practices, and how to do skin self-examinations.~The participant will also complete two surveys for this study, one at baseline and then one at follow up approximately three months later.~Each survey will ask the participant about:~* Current and past skin cancer screening practices~* Current and past sun protection practices~* Attitudes about skin cancer and sun protection~* Knowledge of melanoma

Intervention type: OTHER
Group type: OTHER
Intervention: Surveys & Mailed Materials
Description: Phase I: Patients are screened for their level of risk for skin cancer. They will complete a survey and undergo a skin exam administered by the research staff. Moderate- and high-risk persons will be invited to enroll in Phase II.~Phase II: Three sets of materials will be sent in the mail over the course of 6 weeks. Pamphlets will contain information about ways to reduce participant's risk of skin cancer, including sun protection practices, benefits of skin screening practices, and how to do skin self-examinations.~The participant will also complete two surveys for this study, one at baseline and then one at follow up approximately three months later.~Each survey will ask the participant about:~* Current and past skin cancer screening practices~* Current and past sun protection practices~* Attitudes about skin cancer and sun protection~* Knowledge of melanoma
Study: NCT00458276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tezosentan
Description: Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo (i.e., normal saline) for i.v. use.
Study: NCT03640247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-narcotic group regimen
Description: Non-Narcotic Group. Receives only alternating acetaminophen and ibuprofen

Intervention type: DRUG
Group type: OTHER
Intervention: Narcotic group regimen
Description: Narcotic Group: Alternating acetaminophen and ibuprofen, with a prescription of 10 tablets oxycodone (or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg) for break through pain.
Study: NCT00455845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel IUD
Description: levonorgestrel IUD

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Levonorgestrel IUD
Description: levonorgestrel IUD
Study: NCT04486599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Navigation
Description: The echo-guided sclerotherapy procedure, assisted by electromagnetic navigation, will be carried out in a clean room during the day hospitalisation and followed by a control Echo-Doppler carried out 2 hours after the procedure.
Study: NCT02704013

Intervention type: DRUG
Group type: OTHER
Intervention: Oxybutynin
Description: Anticholinergic
Study: NCT06487663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE with ICI
Description: Transcatheter hepatic artery chemoembolization and immune checkpoint inhibitors
Study: NCT04721769

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic strip craniectomy (with lateral osteotomies) with post-operative helmet therapy
Description: Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic strip craniectomy (without lateral osteotomies) with post-operative helmet therapy
Description: Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.
Study: NCT04042077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: Powder for solution for infusion 300 mg or tablet 450 mg, BID, for 5 to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Powder for solution for infusion 15mg/kg, BID, for 5 to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Solution for infusion or tablet, 600 mg BID, for 5 to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Description: Powder for solution for infusion 4/0.5 g, TID, for 5 to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline
Description: Powder for solution for infusion 50 mg, TID, for 5 to 14 days
Study: NCT01055236

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydroxyzine
Description: 75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydroxyzine
Description: 75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.
Study: NCT03773913

Intervention type: OTHER
Intervention: ICBHSS model
Description: Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers
Study: NCT01530737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin III
Description: Patients randomized to receive Antithrombin concentrate will receive a dose of AT to achieve a target value of 1.2U/ml.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Patients randomized to the control group will receive a placebo consisting of normal saline in a volume equivalent to the volume of antithrombin the same patient in the treatment group would have received and administered by anesthesia and perfusion in the exact same manner as the AT is administered in the treatment group.
Study: NCT02927912

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Electron Beam Therapy
Description: Undergo IOERT boost

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Undergo lumpectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo whole breast radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructive Surgery
Description: Undergo oncoplastic reconstruction
Study: NCT01937975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg oral tablet administered once a day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg oral tablet administered once a day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg oral tablet administered once a day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: 50 mg oral tablet administered once a day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: 50 mg oral tablet administered once a day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: 50 mg oral tablet administered once a day for 10 days
Study: NCT00276835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose interleukin-2
Description: Administered days 1-5, and 15-19; the patient will receive 600,000 IU/kg IL-2 by intravenous infusion over 15 minutes every 8 hours (on day 1 and day 15, patients will receive a maximum of 2 doses per day; on all other days in the cycle patients will receive a maximum of 3 doses per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Description: Starting on day 10 and continuing through day 19, genistein will be administered orally at a dose of 600mg/day in two divided doses (i.e. 300mg po bid x 10 days)
Study: NCT03174665

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT01026129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
Study: NCT00711308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tinzaparin
Description: tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tinzaparin
Description: tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acenocoumarol
Description: acenocoumarol for 6 months
Study: NCT01263509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and voglibose
Description: Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and voglibose
Description: Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
Study: NCT02287233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.
Study: NCT04296747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction chemotherapy
Description: Toripalimab 240mg, d1; docetaxel 75mg/m2 d1; cisplatin 75mg/m2 d1, q21d, for 2 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: After induction chemotherapy, patients with resectable hypopharyngeal cancer would accept surgery within 2-4 weeks and investigator-selected postoperative treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Description: After induction chemotherapy, patients with unresectable hypopharyngeal cancer who achieved CR/PR/SD in the tumor evaluation according to RECIST1.1 would accept another cycle of chemotherapy, and then radical chemoradiotherapy with cisplatin 100mg/m2, q21d
Study: NCT02127125

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: Synbiotic \[5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: Synbiotic \[5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: Synbiotic \[5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer
Description: Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer
Description: Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer
Description: Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks
Study: NCT03345745

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary samples
Description: Salivary Hs-CRP, Fetuin-A and S100A12 levels and salivary flow rates were evaluated at baseline and a month after the treatments

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary samples
Description: Salivary Hs-CRP, Fetuin-A and S100A12 levels and salivary flow rates were evaluated at baseline and a month after the treatments

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary samples
Description: Salivary Hs-CRP, Fetuin-A and S100A12 levels and salivary flow rates were evaluated at baseline and a month after the treatments
Study: NCT02019862

Intervention type: DEVICE
Intervention: TRJ® Total Hip Arthroplasty
Study: NCT03014141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oat bran (Oatwell 28)
Description: 11 g oat bran containing 3.1 gram oat beta-glucan

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 11 g of Maltodextrin
Study: NCT03528382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation quality improvement system
Description: Cardiac rehabilitation quality improvement system is divided into two period. The period I of rehabilitation has three parts, including daily life, rehabilitation exercise training, publicity and education. And the period II of rehabilitation is based on aerobic exercise, as well as combined with resistance and flexibility exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation quality improvement system
Description: Cardiac rehabilitation quality improvement system is divided into two period. The period I of rehabilitation has three parts, including daily life, rehabilitation exercise training, publicity and education. And the period II of rehabilitation is based on aerobic exercise, as well as combined with resistance and flexibility exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation quality improvement system
Description: Cardiac rehabilitation quality improvement system is divided into two period. The period I of rehabilitation has three parts, including daily life, rehabilitation exercise training, publicity and education. And the period II of rehabilitation is based on aerobic exercise, as well as combined with resistance and flexibility exercises
Study: NCT00405938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: anastrozole (1 mg orally daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant).
Study: NCT00572533

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESA Dose Adjustment per standard Anemia Management Protocol
Description: Amount of ESA dose adjustment in Units per week guided by standard Anemia Management Protocol in use at the facility

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESA Dose Adjustment per Smart Anemia Manager Algorithm
Description: Amount of ESA dose adjustment in Units per week individualized to subject's dose-response profile guided by Smart Anemia Manager algorithm
Study: NCT02638597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation counseling
Description: smoking cessation counseling

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: smoking cessation counseling
Description: smoking cessation counseling
Study: NCT02353468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV